Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort.


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
18 05 2022
Historique:
received: 06 01 2022
accepted: 27 04 2022
entrez: 18 5 2022
pubmed: 19 5 2022
medline: 21 5 2022
Statut: epublish

Résumé

This work aimed to investigate the potential pathways involved in the association between social and lifestyle factors, biomarkers of Alzheimer's disease and related dementia (ADRD), and cognition. The authors studied 2323 participants from the Memento study, a French nationwide clinical cohort. Social and lifestyle factors were education level, current household incomes, physical activity, leisure activities, and social network from which two continuous latent variables were computed: an early to midlife (EML) and a latelife (LL) indicator. Brain magnetic resonance imaging (MRI), lumbar puncture, and amyloid-positron emission tomography (PET) were used to define three latent variables: neurodegeneration, small vessel disease (SVD), and AD pathology. Cognitive function was defined as the underlying factor of a latent variable with four cognitive tests. Structural equation models were used to evaluate cross-sectional pathways between social and lifestyle factors and cognition. Participants' mean age was 70.9 years old, 62% were women, 28% were apolipoprotein-ε4 carriers, and 59% had a Clinical Dementia Rating (CDR) score of 0.5. Higher early to midlife social indicator was only directly associated with better cognitive function (direct β = 0.364 (0.322; 0.405), with no indirect pathway through ADRD biomarkers (total β = 0.392 (0.351; 0.429)). In addition to a direct effect on cognition (direct β = 0.076 (0.033; 0.118)), the association between latelife lifestyle indicator and cognition was also mostly mediated by an indirect effect through lower neurodegeneration (indirect β = 0.066 (0.042; 0.090) and direct β =  - 0.116 (- 0.153; - 0.079)), but not through AD pathology nor SVD. Early to midlife social factors are directly associated with higher cognitive functions. Latelife lifestyle factors may help preserve cognitive functions through lower neurodegeneration.

Sections du résumé

BACKGROUND
This work aimed to investigate the potential pathways involved in the association between social and lifestyle factors, biomarkers of Alzheimer's disease and related dementia (ADRD), and cognition.
METHODS
The authors studied 2323 participants from the Memento study, a French nationwide clinical cohort. Social and lifestyle factors were education level, current household incomes, physical activity, leisure activities, and social network from which two continuous latent variables were computed: an early to midlife (EML) and a latelife (LL) indicator. Brain magnetic resonance imaging (MRI), lumbar puncture, and amyloid-positron emission tomography (PET) were used to define three latent variables: neurodegeneration, small vessel disease (SVD), and AD pathology. Cognitive function was defined as the underlying factor of a latent variable with four cognitive tests. Structural equation models were used to evaluate cross-sectional pathways between social and lifestyle factors and cognition.
RESULTS
Participants' mean age was 70.9 years old, 62% were women, 28% were apolipoprotein-ε4 carriers, and 59% had a Clinical Dementia Rating (CDR) score of 0.5. Higher early to midlife social indicator was only directly associated with better cognitive function (direct β = 0.364 (0.322; 0.405), with no indirect pathway through ADRD biomarkers (total β = 0.392 (0.351; 0.429)). In addition to a direct effect on cognition (direct β = 0.076 (0.033; 0.118)), the association between latelife lifestyle indicator and cognition was also mostly mediated by an indirect effect through lower neurodegeneration (indirect β = 0.066 (0.042; 0.090) and direct β =  - 0.116 (- 0.153; - 0.079)), but not through AD pathology nor SVD.
CONCLUSIONS
Early to midlife social factors are directly associated with higher cognitive functions. Latelife lifestyle factors may help preserve cognitive functions through lower neurodegeneration.

Identifiants

pubmed: 35585559
doi: 10.1186/s13195-022-01013-8
pii: 10.1186/s13195-022-01013-8
pmc: PMC9115948
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

68

Subventions

Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Am J Geriatr Psychiatry. 2004 Mar-Apr;12(2):190-200
pubmed: 15010348
Int Psychogeriatr. 2016 Nov;28(11):1791-1806
pubmed: 27502691
Ann Neurol. 2012 Nov;72(5):730-8
pubmed: 23280791
Biol Psychiatry. 2012 May 1;71(9):783-91
pubmed: 22055015
Neuroimage. 2009 Jul 1;46(3):749-61
pubmed: 19236922
Alzheimer Dis Assoc Disord. 2013 Oct-Dec;27(4):343-50
pubmed: 23552443
Neurobiol Aging. 2014 Aug;35(8):1873-82
pubmed: 24656834
JAMA Neurol. 2015 Jun;72(6):699-706
pubmed: 25893879
Cerebrovasc Dis. 2002;13 Suppl 2:31-6
pubmed: 11901240
Brain Imaging Behav. 2017 Apr;11(2):357-367
pubmed: 27544202
Arch Neurol. 2012 May;69(5):623-29
pubmed: 22271235
Neurology. 1988 Jun;38(6):900-3
pubmed: 3368071
PLoS One. 2012;7(11):e48953
pubmed: 23152828
Neurobiol Aging. 2017 Nov;59:72-79
pubmed: 28764930
Brain. 2010 Aug;133(Pt 8):2210-6
pubmed: 20826429
J Neurosci. 2014 Jun 18;34(25):8612-7
pubmed: 24948815
PLoS One. 2008 Jul 09;3(7):e2598
pubmed: 18612379
Neuroinformatics. 2016 Jul;14(3):253-64
pubmed: 27066973
BMC Public Health. 2014 May 27;14:510
pubmed: 24885250
Lancet Neurol. 2020 Jun;19(6):533-543
pubmed: 32470425
Neurobiol Aging. 2020 Apr;88:33-41
pubmed: 31932050
J Neuroradiol. 2014 Dec;41(5):350-7
pubmed: 24485897
Neurology. 2015 Jul 7;85(1):48-55
pubmed: 26062627
Front Aging Neurosci. 2020 Jan 09;11:355
pubmed: 31998113
Brain Imaging Behav. 2017 Apr;11(2):346-356
pubmed: 27757821
Am J Psychol. 1987 Fall-Winter;100(3-4):587-609
pubmed: 3322058
Psychogeriatrics. 2015 Jun;15(2):154-162
pubmed: 25516261
Neurology. 2014 Nov 4;83(19):1753-60
pubmed: 25298312
PLoS One. 2012;7(6):e38268
pubmed: 22675535
Trends Cogn Sci. 2013 Oct;17(10):502-9
pubmed: 24018144
Alzheimers Res Ther. 2017 Aug 29;9(1):67
pubmed: 28851447
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Am J Epidemiol. 1979 Feb;109(2):186-204
pubmed: 425958
Neurobiol Aging. 2016 Apr;40:164-172
pubmed: 26973116
Neurobiol Aging. 2013 Dec;34(12):2827-34
pubmed: 23916061
JAMA Neurol. 2020 Oct 1;77(10):1217-1224
pubmed: 32597941
Cereb Cortex. 2004 Jan;14(1):11-22
pubmed: 14654453
Ann Neurol. 2019 Dec;86(6):866-877
pubmed: 31509621
J Alzheimers Dis. 2018;66(4):1619-1633
pubmed: 30452410
J Alzheimers Dis. 2020;74(1):363-376
pubmed: 32039854
Neuroimage Clin. 2016 May 30;11:802-812
pubmed: 28050342
Ann Nucl Med. 2018 Feb;32(2):75-86
pubmed: 29218458
Arch Clin Neuropsychol. 2004 Mar;19(2):203-14
pubmed: 15010086
Hum Brain Mapp. 2015 Jul;36(7):2826-41
pubmed: 25879865
Front Aging Neurosci. 2018 Mar 22;10:70
pubmed: 29623037
Arch Neurol. 1978 Jun;35(6):364-7
pubmed: 655909
Alzheimers Dement. 2020 Sep;16(9):1305-1311
pubmed: 30222945
Neuroimage. 2012 Nov 1;63(2):936-46
pubmed: 22510256
Neuroimage. 2007 Feb 1;34(3):996-1019
pubmed: 17178234
Public Health Nutr. 2006 Sep;9(6):755-62
pubmed: 16925881

Auteurs

Leslie Grasset (L)

University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inserm, CIC1401-EC, F-33000, Bordeaux, France. leslie.grasset@u-bordeaux.fr.

Cécile Proust-Lima (C)

University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inserm, CIC1401-EC, F-33000, Bordeaux, France.

Jean-François Mangin (JF)

CATI Multicenter Neuroimaging Platform, 75000, Paris, France.
Neurospin CEA Paris Saclay University, 91190, Gif-sur-Yvette, France.

Marie-Odile Habert (MO)

CATI Multicenter Neuroimaging Platform, 75000, Paris, France.
Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, F-75006, Paris, France.
AP-HP, Hôpital Pitié-Salpêtrière, Médecine Nucléaire, 75013, Paris, France.

Bruno Dubois (B)

IM2A AP-HP INSERM UMR-S975 Groupe Hospitalier Pitié-Salpêtrière Institut de La Mémoire Et de La Maladie d'Alzheimer, Institut du Cerveau Et de La Moelle Épinière Sorbonne, Université Paris, Paris, France.

Claire Paquet (C)

Centre de Neurologie Cognitive Hôpital Lariboisière, Université de Paris, INSERMU1144, F-75010, Paris, France.

Olivier Hanon (O)

Geriatric Department Broca Hospital, Université Paris Descartes, Sorbonne Paris Cité, APHP, EA 4468, F-75013, Paris, France.

Audrey Gabelle (A)

Centre Mémoire Ressources Recherche Département de Neurologie CHU Gui de Chauliac, 34000, Montpellier, France.
Inserm U1061, La Colombière Université de Montpellier, 34000, Montpellier, France.

Mathieu Ceccaldi (M)

CMMR PACA Ouest CHU Timone APHM & Aix Marseille Univ INSERM INS Inst Neurosci Syst, 13000, Marseille, France.

Cédric Annweiler (C)

Department of Geriatric Medicine, Research Center On Autonomy and Longevity; UPRES EA 4638, Angers University HospitalAngers University Memory ClinicUniversity of Angers, 49000, Angers, France.
Department of Medical Biophysics, Schulich School of Medicine and Dentistry, Robarts Research Institute, the University of Western Ontario, London, ON, Canada.

Renaud David (R)

Centre Mémoire de Ressources et de Recherche (CMRR) - CHU Nice, Centre de Recherche Edmond Et Lily SAFRA, CoBTeK "Cognition Behaviour Technology" - Université Côte d'Azur, Institut Claude Pompidou, EA 7276, 06000, Nice, France.

Therese Jonveaux (T)

Centre Mémoire de Ressources Et de Recherche de Lorraine, Laboratoire Lorrain de Psychologie Et de Neurosciences de La Dynamique Des Comportements, Unité Cognitivo Comportementale CHRU Nancy, Université de Lorraine, 2LPN EA 7489, 54000, Nancy, France.

Catherine Belin (C)

Service de Neurologie Hôpital Saint-Louis AP-HP, 75010, Paris, France.

Adrien Julian (A)

Service de Neurologie CHU La Milétrie Centre Mémoire de Ressources Et de Recherche, 86000, Poitiers, France.

Isabelle Rouch-Leroyer (I)

Cellule Régionale d'observation de La Maladie d'Alzheimer Et Des Maladies Apparentées, CHU de Saint Etienne, 42000, Saint-Etienne, France.

Jérémie Pariente (J)

Department of Neurology, Toulouse University Hospital, 31000, Toulouse, France.
Toulouse NeuroImaging Center, Universite de Toulouse, Inserm, UPS, 31000, Toulouse, France.

Maxime Locatelli (M)

CATI Multicenter Neuroimaging Platform, 75000, Paris, France.
Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB, F-75006, Paris, France.
Institut du Cerveau Et de La Moelle Épinière, CNRS, Inserm, UMR 7225, U 1127, Sorbonne Université, CATI, F-75013, Paris, France.

Marie Chupin (M)

CATI Multicenter Neuroimaging Platform, 75000, Paris, France.
Institut du Cerveau Et de La Moelle Épinière, CNRS, Inserm, UMR 7225, U 1127, Sorbonne Université, CATI, F-75013, Paris, France.

Geneviève Chêne (G)

University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inserm, CIC1401-EC, F-33000, Bordeaux, France.
Pole de Sante Publique Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000, Bordeaux, France.

Carole Dufouil (C)

University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219; Inserm, CIC1401-EC, F-33000, Bordeaux, France.
Pole de Sante Publique Centre Hospitalier Universitaire (CHU) de Bordeaux, 33000, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH